文献速递冠心病外科心外重症与机械循环支持

高危微轴流泵(Impella 5.5)用于急性心肌梗死合并心源性休克的临床结局

Clinical outcomes in acute myocardial infarction cardiogenic shock patients supported with a high-flow, surgically implanted micro-axial flow pump.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-01-16

本研究基于前瞻性多中心注册研究,纳入177例急性心肌梗死合并心源性休克患者,比较单独使用Impella 5.5与联合其他临时机械循环支持装置的结局。

核心结论

  • 急性心肌梗死合并心源性休克患者使用Impella 5.5时,多数联合其他临时机械循环支持装置。
  • 单独使用Impella 5.5者住院生存率有升高趋势,且30天生存率显著更高、溶血发生率显著更低。

研究设计与样本

  • 前瞻性、多中心、观察性注册研究(Surgical Unloading Renal Protection and Sustainable Support研究),纳入15个中心2020年8月至2023年12月收治的177例急性心肌梗死合并心源性休克患者。
  • 排除使用静脉-动脉和静脉-静脉体外膜氧合的患者。
  • 按是否联合其他非ECMO临时机械装置分为单独Impella 5.5组(n=55,31%)和Impella 5.5+其他tMCS组(n=122,69%)。

主要发现

  • 存活者中78%为自体心脏存活,4%接受心脏移植,11%接受持久性左心室辅助装置植入。
  • 支持期间不良事件:卒中4%,溶血9%,全因出血16%,急性肾损伤23%。

临床怎么用

  • 对于急性心肌梗死合并心源性休克患者,单独使用Impella 5.5可能与更高的30天生存率和更低的溶血风险相关。
  • 应关注联合使用其他临时机械循环支持装置时的溶血等不良事件风险。

局限性

  • 本研究为观察性注册研究,非随机设计,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Impella micro-axial pumps are increasingly used in cardiogenic shock. Recent randomized controlled data showed a survival benefit with use of the Impella CP in ST-elevation myocardial infarction-related cardiogenic shock. Use of the Impella 5.5, a high-flow surgically implanted micro-axial pump, in patients with acute myocardial infarction cardiogenic shock remains largely unexplored. We analyzed data from the Surgical Unloading Renal Protection and Sustainable Support study, a prospective, multicenter, observational registry evaluating real-world outcomes in patients with acute myocardial infarction cardiogenic shock supported with the Impella 5.5. METHODS: Patients with cardiogenic shock enrolled in Surgical Unloading Renal Protection and Sustainable Support study at 15 sites between August 2020 and December 2023 were included and stratified into those receiving the Impella 5.5 only versus other non-extracorporeal membrane oxygenation forms of temporary mechanical devices before or during Impella 5.5 (Impella 5.5 + other temporary mechanical circulatory support devices). In this analysis, patients receiving venoarterial and venovenous extracorporeal membrane oxygenation were excluded. In-hospital outcomes and longitudinal survival were studied, specifically adverse events while on support and survival at hospital discharge, 30 days, and 1 year. RESULTS: Among 177 patients with acute myocardial infarction cardiogenic shock, 31% (n = 55) received only an Impella 5.5 and 69% (n = 122) received an Impella 5.5 + other tMCS. Their mean age was 61 ± 12 years, and 80% of subjects were male. Comorbidities included diabetes (49%), hypertension (67%), heart failure (34%), peripheral vascular disease (17%), and previous stroke (8%). Overall in-hospital survival was 65%, with higher survival among patients with only an Impella 5.5 (75% vs 61%, P = .089). Among all survivors, 78% had native heart survival, 4% underwent heart transplant, and 11% underwent durable left ventricular assist device placement. Adverse events while on support included stroke (4%), hemolysis (9%), all-cause bleeding (16%), and acute kidney injury (23%). Hemolysis was lower among patients with only an Impella 5.5 (1.8% vs 12.3%, P < .05). The 30-day survival was 81.7% for the Impella 5.5 alone group and 66.0% for the Impella 5.5 + temporary mechanical circulatory support devices group (P = .044): 6-month survival of 64.8% versus 51.8% (P = .081) and 12-month survival of 58.0% versus 46% (P = .090). CONCLUSIONS: There is considerable variation in how the Impella 5.5 is used to treat patients with acute myocardial infarction cardiogenic shock, with the majority of patients being exposed to other forms of temporary mechanical circulatory support devices. The majority of patients were discharged on their native heart, and patients supported with only the Impella 5.5 had a trend toward higher survival and significantly lower all-cause bleeding, hemolysis, and stroke rates.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Anderson M, Zeeshan A, Katlaps GJ, et al. Clinical outcomes in acute myocardial infarction cardiogenic shock patients supported with a high-flow, surgically implanted micro-axial flow pump. J Thorac Cardiovasc Surg. 2026. PMID: 41548842. doi:10.1016/j.jtcvs.2025.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。